U.S. pharma giant copyright scrapped two experimental weight loss products final 12 months—a after-daily tablet, lotiglipron, due to elevated liver enzymes and also a twice-day by day tablet, danuglipron, on account of potent Negative effects—but CEO Albert Bourla has claimed the com